BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32955183)

  • 1. Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents.
    Santoro M; Romano A; Mancuso S; Siragusa S; DI Raimondo F; Martinelli G; Cerchione C
    Panminerva Med; 2021 Mar; 63(1):1-6. PubMed ID: 32955183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
    Al-Ani F; Bermejo JM; Mateos MV; Louzada M
    Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
    Larocca A; Cavallo F; Bringhen S; Di Raimondo F; Falanga A; Evangelista A; Cavalli M; Stanevsky A; Corradini P; Pezzatti S; Patriarca F; Cavo M; Peccatori J; Catalano L; Carella AM; Cafro AM; Siniscalchi A; Crippa C; Petrucci MT; Yehuda DB; Beggiato E; Di Toritto TC; Boccadoro M; Nagler A; Palumbo A
    Blood; 2012 Jan; 119(4):933-9; quiz 1093. PubMed ID: 21835953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.
    Leleu X; Rodon P; Hulin C; Daley L; Dauriac C; Hacini M; Decaux O; Eisemann JC; Fitoussi O; Lioure B; Voillat L; Slama B; Al Jijakli A; Benramdane R; Chaleteix C; Costello R; Thyss A; Mathiot C; Boyle E; Maloisel F; Stoppa AM; Kolb B; Michallet M; Lamblin A; Natta P; Facon T; Elalamy I; Fermand JP; Moreau P
    Thromb Haemost; 2013 Oct; 110(4):844-51. PubMed ID: 23903204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
    Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
    Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations.
    Swan D; Rocci A; Bradbury C; Thachil J
    Br J Haematol; 2018 Nov; 183(4):538-556. PubMed ID: 30450656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
    Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
    Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the venous thrombotic issues associated with multiple myeloma.
    Fotiou D; Gerotziafas G; Kastritis E; Dimopoulos MA; Terpos E
    Expert Rev Hematol; 2016 Jul; 9(7):695-706. PubMed ID: 27232265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
    Zangari M; Fink L; Zhan F; Tricot G
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.
    Palmaro A; Rougé-Bugat ME; Gauthier M; Despas F; Moulis G; Lapeyre-Mestre M
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):578-586. PubMed ID: 28198064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
    Cornell RF; Goldhaber SZ; Engelhardt BG; Moslehi J; Jagasia M; Harrell S; Rubinstein SM; Hall R; Wyatt H; Piazza G
    Br J Haematol; 2020 Aug; 190(4):555-561. PubMed ID: 32314352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
    Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
    Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombosis in myeloma treated with IMiDs.
    Leleu X
    Thromb Res; 2012 Oct; 130 Suppl 1():S63-5. PubMed ID: 23026667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
    Uaprasert N; Voorhees PM; Mackman N; Key NS
    Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?].
    de Moreuil C; Ianotto JC; Eveillard JR; Carrier M; Delluc A
    Rev Med Interne; 2016 Jul; 37(7):473-9. PubMed ID: 26833146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
    Palumbo A; Cavo M; Bringhen S; Zamagni E; Romano A; Patriarca F; Rossi D; Gentilini F; Crippa C; Galli M; Nozzoli C; Ria R; Marasca R; Montefusco V; Baldini L; Elice F; Callea V; Pulini S; Carella AM; Zambello R; Benevolo G; Magarotto V; Tacchetti P; Pescosta N; Cellini C; Polloni C; Evangelista A; Caravita T; Morabito F; Offidani M; Tosi P; Boccadoro M
    J Clin Oncol; 2011 Mar; 29(8):986-93. PubMed ID: 21282540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombosis in multiple myeloma.
    Zangari M; Elice F; Fink L; Tricot G
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system.
    Parnes A; Leblebjian H; Hamilton J; Smith S; Laubach J; Berliner N
    J Oncol Pharm Pract; 2022 Mar; 28(2):421-424. PubMed ID: 33611974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.